Unknown

Dataset Information

0

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.


ABSTRACT:

Background/aims

Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affecting PFS of crizotinib and develop a prognostic model for advanced ALK-positive NSCLC.

Methods

Clinicopathologic features of patients enrolled in PROFILE 1001, 1005, 1007, and 1014 (training cohort) were reviewed. We conducted multivariate Cox analysis for PFS and overall survival (OS) in the training cohort (n = 159) and generated a proportional hazards model based on significant clinicopathologic factors, and then validated the model in an independent validation cohort (n = 40).

Results

In the training cohort, the objective response rate was 81.5%. Median PFS and OS from the start of crizotinib were 12.4 and 31.3 months, respectively. Multivariate Cox analysis showed poor performance status, number of metastatic organs (? 3), and no response to crizotinib independently associated shorter PFS. Based on a score derived from these three factors, median PFS and OS of patients with one or two factors were significantly shorter compared to those without these factors (median PFS, 22.4 months vs. 10.5 months vs. 6.5 months; median OS, not reached vs. 29.1 months vs. 11.8 months, respectively; p < 0.001 for each group). This model also had validated in an independent validation cohort.

Conclusion

Performance status, number of metastatic organs, and response to crizotinib affected PFS of crizotinib in ALK-positive NSCLC. Based on these factors, we developed a simple and useful prediction model for PFS.

SUBMITTER: Ock CY 

PROVIDER: S-EPMC6718771 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.

Ock Chan-Young CY   Yoo Shin-Hye SH   Keam Bhumsuk B   Kim Miso M   Kim Tae Min TM   Jeon Yoon Kyung YK   Kim Dong-Wan DW   Chung Doo Hyun DH   Heo Dae Seog DS  

The Korean journal of internal medicine 20180629 5


<h4>Background/aims</h4>Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affecting PFS of crizotinib and develop a prognostic model for advanced ALK-positive NSCLC.<h4>Methods</h4>Clinicopathologic features of patients enrolled in PROFILE 1001, 1005, 1007, and 1014 (trai  ...[more]

Similar Datasets

| S-EPMC4470734 | biostudies-literature
| S-EPMC4630528 | biostudies-literature
| S-EPMC7867779 | biostudies-literature
| S-EPMC6010493 | biostudies-literature
| S-EPMC5789360 | biostudies-literature
| S-EPMC6056984 | biostudies-literature
| S-EPMC5400633 | biostudies-literature
| S-EPMC6119621 | biostudies-literature
| S-EPMC6718030 | biostudies-literature